Abstract
Recombinant adenoviruses encoding murine IL-2 gene or IL-3 gene were directly injected into established subcutaneous tumor model of G422 glioblastoma cells. After treatment, the tumor size and survival of the glioblastoma-bearing mice were observed. The splenic NK and CTL cytotoxicities were detected by standard 4-hour51Cr release assay. We also examined the histopathological changes of tumor by hematoxylin and eosin staining. The results showed that intratumoral injection of adenoviruses encoding murine IL-2 gene or IL-3 gene significantly inhibited the growth of G422 glioblastoma and prolonged the survival period of glioblastoma-bearing mice. The CTL cytotoxicity of the gene therapy groups was significantly higher than that of the control groups, but NK activity remained unchanged, indicating that specific immunity contributes to the in vivo antitumor effect of the direct gene therapy. There were much more tumor necrosis and inflammatory cell infiltration in the tumor of the gene therapy groups. Combined IL-2/IL-3 gene therapy could induce higher level of CTL and enhance the therapeutic potential further. The results suggest that intratumoral injection of recombinant adenoviruses encoding certain kind of cytokines may be a useful approach in the treatment of a malignancy of the central nervous system.
Similar content being viewed by others
References
Kim TS, Halliday AL, Hedley-Whyte ET, et al. Correlates of survival and the Daumas-Duport grading system for astrocytomas. J Neurosurg 1990; 72:354.
Devaux BC, O’Fallon JR, Kelly PJ. Resection, biopsy, and survival in malignant glial neoplasms. A retrospective study of clinical parameters, therapy, and outcome. J Neurosurg 1993; 78:767.
Watne K, Hannisdal E, Nome O, et al. Combined intra-arterial and systemic chemotherapy for recurrent malignant brain tumors. Neurosurgery 1992; 30:223.
Kruse CA, Roper MD, Kleinschmidt-DeMasters BK, et al. Purified herpes simplex thymidine kinase Retrovector™ particles. I. In vitro characterization, in situ transduction efficiency, and histopathological analyses of gene therapy-treated brain tumors. Cancer Gene Ther 1997; 4:118.
Kun LE, Gajjar A, Muhlbauer M,et al. Clinical protocol: Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-GlTklSvNa.7) and intravenous Ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors. Hum Gene Ther 1995; 6:1231.
1996; 26:271.
Le Gal La Salle G, Robert JJ, Berrard S, et al. An adenovirus vector for gene transfer into neurons and glia in the brain. Science 1993; 259:988.
Viola JJ, Ram Z, Walbridge S, et al. Adenovirally mediated gene transfer into experimental solid brain tumors and leptomeningeal cancer cells. J Neurosurg 1995; 82:70.
Gasti G, Finstad CL, Guarini A, et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992; 52:6229.
Ohe Y, Podack ER, Olsen KJ, et al. Combination effect of vaccination with 1L2 and 1L4 cDNA transfected cells on the induction of a therapeutic immune response against Lewis lung carcinoma cells. Int J Cancer 1993; 53:432.
Author information
Authors and Affiliations
Additional information
This work was supported by grants from the National Natural Science Foundation of China (No. 39421009).
Rights and permissions
About this article
Cite this article
Hong, B., Cao, X., Yu, Y. et al. Combined IL-2/IL-3 gene therapy for g422 mouse glioblastoma by intratumoral injection of recombinant adenoviruses. Chin J Cancer Res 9, 285–289 (1997). https://doi.org/10.1007/BF02974976
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02974976